EGFR and non-small cell lung carcinoma: Moreover, two clinical studies showed that SNPs in EGFR exons 18, 19, 21, and 25 affect the clinical efficacy of gefitinib and may be potential biomarkers for the prediction of the clinical outcome of gefitinib-treated patients with advanced non-small cell lung cancer (NSCLC ) [50], [51].